Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Alexion

Drug and asset intelligence for Alexion with 6 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 6
Catalysts: 0
Stage: Development stage unavailable

Recent signals(6)

ClinicalJuly 27, 2026

Ravulizumab Study in Chinese Adults with Generalized Myasthenia Gravis Initiated by Alexion

A clinical trial is underway to assess the efficacy and safety of ravulizumab in Chinese adults with generalized myasthenia gravis.

ClinicalJuly 22, 2026

Alexion's Ravulizumab Shows Promise in Pediatric NMOSD Study

A clinical trial is underway to assess the safety and efficacy of ravulizumab in children with NMOSD.

RegulatoryJuly 22, 2026

FDA Approves Supplement for ULTOMIRIS (Ravulizumab-Cwvz)

The FDA has approved a supplemental application for ULTOMIRIS, indicating a significant regulatory milestone for Alexion Pharmaceuticals.

RegulatoryJuly 9, 2026

FDA Accepts Supplement Application for Soliris (Eculizumab) by Alexion Pharmaceuticals

The FDA has accepted a supplemental application for Soliris, an eculizumab-based therapy.

RegulatoryJuly 8, 2026

FDA Acceptance of Supplement for BLA761340 by Samsung Bioepis

The FDA has accepted the supplemental biologics license application for EPYSQLI (eculizumab-aagh) from Samsung Bioepis.

RegulatoryJuly 8, 2026

FDA Accepts Supplement Application for Eculizumab-AAGH by Samsung Bioepis

The FDA has accepted the supplemental application for BLA761340, a biosimilar of eculizumab.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Therapeutic areas

Complement Inhibition →

Myasthenia Gravis →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.